The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: A placebo-controlled study

Journal of Clinical Psychiatry

Volumn 74, Issue 6, 2013, Pages 587-594

  Heun, Reinhard ^a   Ahokas, Antti ^b   Boyer, Patrice ^c,d   Giménez Montesinos, Natalia ^e   Pontes Soares, Fernando ^e   Olivier, Valérie ^e  

^a DERBY CITY GENERAL HOSPITAL   (United Kingdom)

^b Mehilainen Oy   (Finland)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARGENTINA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; FINLAND; GERIATRIC PATIENT; HAMILTON SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEXICO; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PORTUGAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; RHINOPHARYNGITIS; ROMANIA; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; HAMILTON DEPRESSION RATING SCALE; HEADACHE; TREATMENT OUTCOME;

EID: 84879591654     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08250     Document Type: Article

References (33)

1. Lyness JM, Caine ED, King DA, et al. Depressive disorders and symptoms in older primary care patients: one-year outcomes. Am J Geriatr Psychiatry. 2002;10(3):275-282. PubMed
2. Bergdahl E, Gustavsson JM, Kallin K, et al. Depression among the oldest old: the Umea 85+ study. Int Psychogeriatr. 2005;17(4):557-575. doi:10.1017/S10416102050267 PubMed
3. Luppa M, Sikorski C, Luck T, et al. Age- and gender-specific prevalence of depression in latest-life - systematic review and meta-analysis. J Affect Disord. 2012;136(3):212-221. doi:10.1016/j.jad.2010.1.03 PubMed
4. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900-909. doi:10.176/api.ajp.164.6.90 PubMed
5. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol. 2008;28(1):32-38. doi:10.1097/jcp. 0b013e318160738e PubMed
6. Schneider LS, Nelson JC, Clary CM, et al; Sertraline Elderly Depression Study Group. An 8-week multicenter, parallel-group, double-blind, placebocontrolled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003;160(7):1277-1285. doi:10.176/api.ajp.160.7.127 PubMed
7. Rossini D, Serretti A, Franchini L, et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol. 2005;25(5):471-475. doi:10.1097/01.jcp.017548.28961.e7 PubMed
8. Sheikh JI, Cassidy EL, Doraiswamy PM, et al. Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc. 2004;52(1):86-92. doi:10.1/j.1532-5415.204. 52015.x PubMed
9. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64(9):1065-1074. doi:10.408/JCP.v64n0912 PubMed
10. Rapaport MH, Lydiard RB, Pitts CD, et al. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebocontrolled trial. J Clin Psychiatry. 2009;70(1):46-57. doi:10.408/JCP.06m0296 PubMed
11. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry. 2004;19(12):1123-1130. doi:10.102/gps.190 PubMed
12. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry. 2006;14(4):361-370. doi:10.1097/01.JGP.0194645.70869.3b PubMed
13. Roose SP, Sackeim HA, Krishnan KR, et al; Old-Old Depression Study Group. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry. 2004;161(11):2050-2059. doi:10.176/api.ajp.161.1.2050 PubMed
14. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16(1):14-20. doi:10.1097/JGP.0b013e3181591c09 PubMed
15. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebocontrolled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-223. doi:10.1097/YIC. 0b013e3283542457 PubMed
16. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558-567. doi:10.1097/01.JGP.03083.64832.ed PubMed
17. Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebocontrolled randomized trials. J Clin Psychiatry. 2011;72(12):1660-1668. doi:10.408/JCP.10r06531 PubMed
18. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628-642. PubMed
19. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378(9791):621-631. doi:10.1016/S0140-6736(1)6095-0 PubMed
20. DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry. 1999;60(suppl 20):38-44. PubMed
21. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry. 1999;60(suppl 20):4-8. PubMed
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
23. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication ADM 76-338. Rockville MD: National Institute of Mental Health; 1976:217-222.
24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi:10.1/j.160-047.1983.tb09716.x PubMed
25. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/02-3956(75)9026-6 PubMed
26. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709-711. PubMed
27. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95. doi:10.1097/04850-1960603-015 PubMed
28. Braam AW, Prince MJ, Beekman AT, et al. Physical health and depressive symptoms in older Europeans: results from EURODEP. Br J Psychiatry. 2005;187(1):35-42. doi:10.192/bjp.187.1.35 PubMed
29. Jeste ND, Hays JC, Steffens DC. Clinical correlates of anxious depression among elderly patients with depression. J Affect Disord. 2006;90(1):37-41. doi:10.1016/j.jad.205.10.07 PubMed
30. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord. 1997;46(3):191-217. doi:10.1016/S0165-0327(97)0107-9 PubMed
31. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24(6):479-499. doi:10.2165/153420-0-0 PubMed
32. Wise TN, Wiltse CG, Iosifescu DV, et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract. 2007;61(8):1283-1293. doi:10.1/j.1742-1241.207.01476.x PubMed
33. Avins AL. Can unequal be more fair? ethics, subject allocation, and randomised clinical trials. J Med Ethics. 1998;24(6):401-408. doi:10.136/jme.24.6.401 PubMed